Episode 24023
FDA Approval! A New Model for BioPharma... Dr. Sam Blackman, Founder & Head of Research and Development, Day One Biopharmaceuticals
BioTech Nation ... with Dr. Moira Gunn · Moira Gunn
June 26, 202431m 10s
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
This week on BioTech Nation, Dr. Sam Blackman, Founder and Head of Research and Development from Day One Biopharmaceuticals, shares the story behind the FDA approval of a groundbreaking drug for the most common childhood brain cancer. He talks about their innovative approach to starting a biopharma company and how it led to a newly FDA approved drug that treats the most common form of brain cancer in children
Topics
Pediatric oncologyBrain cancerDay 1 BiopharmaceuticalsFDA approvalTovorafenibBRAF alterationFireFLY trialChildhood cancerInnovationBreakthroughHopeDrug development